Blueprint Medicines Corporation - Common Stock (BPMC)
128.10
+0.00 (0.00%)
NASDAQ · Last Trade: Jun 5th, 6:06 AM EDT
Detailed Quote
Previous Close
128.10
Open
-
Bid
127.20
Ask
128.25
Day's Range
N/A - N/A
52 Week Range
73.04 - 121.90
Volume
10
Market Cap
8.14B
PE Ratio (TTM)
-51.65
EPS (TTM)
-2.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
783,263
Chart
About Blueprint Medicines Corporation - Common Stock (BPMC)
Blueprint Medicines Corporation is a biotechnology company that focuses on developing targeted therapies for patients with genomically defined cancers, rare diseases, and cancer-related conditions. The company's innovative approach centers around understanding specific genetic mutations that drive diseases, allowing them to design and produce precision medicines that can more effectively address the underlying causes of these conditions. With a commitment to advancing cancer treatment, Blueprint Medicines aims to improve patient outcomes by delivering personalized therapies based on individual genetic profiles. Read More
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Blueprint Medicines Corporation (NasdaqGS: BPMC) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Blueprint will receive $129.00 per share in cash at closing, and also will receive one non-tradeable contingent value right (CVR) entitling the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.
The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi.
Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Blueprint Medicines Corporation (NASDAQ: BPMC) to Sanofi is fair to Blueprint shareholders. Under the terms of the proposed transaction, Sanofi will pay $129.00 per share in cash at closing, and Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) entitling the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808.
